Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines

References

• Enders J, Weller T, Robbins F. Cultivation of the Lansing strain of poliomyelitis virus in cultures of various human embryonic tissues. Science109, 85–87 (1949).
   PubMed Web of Science ®Google Scholar
• Plotkin SL, Plotkin SA. A short history of vaccination. In: Vaccines (5th Edition). Plotkin SA, Orenstein WA, Offit PA (Eds). Saunders Elsevier, PA, USA 1–16 (2008).
   Google Scholar
• Plotkin SA, Vidor E. Poliovirus vaccine – inactivated. In: Vaccines (5th Edition). Plotkin SA, Orenstein WA, Offit PA (Eds). Saunders Elsevier, PA, USA 605–629 (2008).
   Google Scholar
• Dang-Tan T, Mahmud SM, Puntoni R, Franco EL. Polio vaccines, Simian v September irus 40, and human cancer: the epidemiologic evidence for a causal association. Oncogene23, 6535–6540 (2004).
   PubMedGoogle Scholar
• Hayflick L, Moorehead PS. The serial cultivation of human diploid cell substrates. Exp. Cell. Res.25, 585–621 (1961).
   PubMed Web of Science ®Google Scholar
• Plotkin SA. Rabies vaccine prepared in human cell cultures: progress and perspectives. Rev. Infect. Dis.2, 433–448 (1980).
   PubMedGoogle Scholar
• US Department of Health, Education and Welfare, Public Health Service. Regulation for the Manufacture of Biological Products, title 42, part 73. DHEW pub. No. (NIH) 71–161, formerly PHS publ. No. 437, revised 1971–1976.
   Google Scholar
• Cells, Products, Safety. Backgrounds papers from the WHO Study Group on Biologicals. Dev. Biol. Standard.68, 1–90 (1987).
   Google Scholar
• Yasumura Y, Kawakita Y. Study of SV40 in tissue culture. Nippon Rinsho.21, 1201–1205 (1963).
   Google Scholar
• Horaud F. Absence of viral sequences in the WHO-Vero cell bank a collaborative study. Dev. Biol. Standard.76, 43–46 (1992).
   PubMedGoogle Scholar
• Levenbook IS, Petricciano JC, Elisberg BL. Tumorigenicity of Vero cells. J. Biol. Stand.12, 391–398 (1984).
   PubMedGoogle Scholar
• Furesz J, Fanok A, Contreras G, Becker B. Tumorigenicity testing of various cell line substrates for production of biologicals. Dev. Biol. Stand.70, 233–243 (1989).
   PubMedGoogle Scholar
• Vincent-Falquet JC, Peyron L, Souvras M, Moulin JC, Tektoff J, Patet J. Qualification of working cell banks for the Vero cell line to produce licensed human vaccines. Dev. Biol. Stand.70, 153–156 (1989).
   PubMedGoogle Scholar
• Montagnon BJ, Vincent-Falquet JC, Saluzzo JF. Experience with Vero cells at Pasteur Mérieux Connaught. Dev. Biol. Stand.98, 137–140 (1999).
   PubMedGoogle Scholar
• WHO. Biological Substances No. 37. Requirements for continuous cell lines used for biologicals production. WHO technical report series, No. 745, 1987, Annex 3.
   Google Scholar
• European Pharmacopoeia. Cell substrates for the production of vaccines for human use 2005: 50203 (2005).
   Google Scholar
• US Department of Health and Human Services FDA. Guidance for industry: characterization and qualification of cell substrates and other biological starting materials used in the production of viral vaccines for the prevention and treatment of infectious disease (2006).
   Google Scholar
• ICH Guidance Q5D: Derivation and characterization of cell substrates used for production of biotechnological/biological products. 63 FR 50244; 21 September, 1998.
   Google Scholar
• Palache AM, Brands R, van Scharrenburg GJM. Immunogenicity and reactogenicity of influenza subunit vaccines produced in MDCK cells or fertilized chicken eggs. J. Infect. Dis.176, 20–23 (1997).
   PubMed Web of Science ®Google Scholar
• Pau MG, Ophorst C, Koldijk MH, Schouten G, Mehtali M, Uytdehaag F. The human cell line PER-C6 provides a new manufacturing system for the production of influenza vaccines. Vaccine19, 2716–2721 (2001).
   PubMed Web of Science ®Google Scholar
• Montagnon BJ, Fanget B, Nicolas AJ. The large-scale cultivation of Vero cells in microcarrier culture for virus vaccine production: preliminary results for killed poliovirus vaccine. Dev. Biol. Stand.47, 55–64 (1981).
   PubMedGoogle Scholar
• Sutter RW, Kew OM, Cochi SL. Poliovirus vaccine – live. In: Vaccines (5th Edition). Plotkin SA, Orenstein WA, Offit PA (Eds). Saunders Elsevier, PA, USA 631–685 (2008).
   Google Scholar
• Vidor E, Meschievitz C, Plotkin S. Fifteen years of experience with Vero-produced enhanced potency inactivated poliovirus vaccine. Pediatr. Infect. Dis. J.16, 312–322 (1997).
   PubMed Web of Science ®Google Scholar
• Rhim JS, Schell K, Creasy B, Case W. Biological characteristics and viral susceptibility of an African green monkey kidney cell line (Vero). Proc. Soc. Exp. Biol. Med.132, 670–678 (1969).
   PubMed Web of Science ®Google Scholar
• Desmyter J, Melnick JL, Rawls WE. Defectiveness of interferon production and of Rubella virus interference in a line of African green monkey kidney cells (Vero). J. Virol.2, 955–961 (1968).
   PubMed Web of Science ®Google Scholar
• Van Wezel AL, Van Steenis G, Hannik CA, Cohen H. New approach to the production of concentrated and purified inactivated polio and rabies tissue culture vaccines. Dev. Biol. Stand.41, 159–168 (1978).
   PubMedGoogle Scholar
• Kistner O, Barrett PN, Mundt W, Reiter M, Schober-Bendixen S, Dorner F. Development of a mammalian cell (Vero) derived candidate influenza virus vaccine. Vaccine16, 960–968 (1998).
   PubMed Web of Science ®Google Scholar
• Spruth M, Kistner O, Savidis-Dacho H et al. A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralizing and protective antibody responses. Vaccine24, 652–661 (2006).
   PubMed Web of Science ®Google Scholar
• Kistner O, Howard K, Spruth M et al. Cell culture (Vero) derived whole-virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine25, 6028–6036 (2007).
   PubMed Web of Science ®Google Scholar
• Ehrlich HJ, Müller M, Oh HML et al. A cell culture (Vero) derived whole virus H5N1 vaccine is safe and induces antibody responses: results of a Phase I/II randomized controlled clinical trial. N. Engl. J. Med.358, 2573–2584 (2008).
   PubMed Web of Science ®Google Scholar
• Dennehy PH. Rotavirus vaccines: an overview. Clin. Microbiol. Rev.21, 198–208 (2008).
   PubMed Web of Science ®Google Scholar
• Clark HF, Offit PA, Plotkin SA, Heaton PM. The new pentavalent rotavirus vaccine composed of bovine (strain WC3) – human rotavirus reassortants. Pediatr. Infect. Dis. J.25, 577–583 (2006).
   PubMed Web of Science ®Google Scholar
• Vesikari T, Giaquinto C, Huppertz HI. Clinical trials of rotavirus vaccines in Europe. Pediatr. Infect. Dis. J.25, 42–47 (2006).
   PubMed Web of Science ®Google Scholar
• Bernstein DI. Live attenuated human rotavirus vaccine, Rotarix. Semin. Pediatr. Infect. Dis.17, 188–194 (2006).
   PubMedGoogle Scholar
• O’Ryan M. Rotarix (RIX4414): an oral human rotavirus vaccine. Expert Rev. Vaccines6, 11–19 (2007).
   PubMed Web of Science ®Google Scholar
• Ruiz-Palacios GM, Perez-Schael I, Velazquez FR et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N. Engl. J. Med.354, 11–22 (2006).
   PubMed Web of Science ®Google Scholar
• Kitano T, Oya A. Japanese encephalitis vaccine. In: Vaccine Handbook. Researcher’s Associates TNIoH (Ed.). Maruzen, Tokyo 103–113 (1996).
   Google Scholar
• Sugawara K, Nishiyama K, Ishikawa Y et al. Development of Vero cell-derived inactivated Japanese encephalitis vaccine. Biologicals30, 303–314 (2002).
   PubMed Web of Science ®Google Scholar
• Mackenzie JS, Gubler DJ, Petersen LR. Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat. Med.10, 98–109 (2004).
   PubMed Web of Science ®Google Scholar
• Jelinek T. Japanese encephalitis vaccine in travelers. Expert Rev. Vaccines7, 689–693 (2008).
   PubMed Web of Science ®Google Scholar
• Tauber E, Kollaritsch H, Korinek M et al. Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, Phase III, randomised controlled trial. Lancet370, 1847–1853 (2007).
   PubMed Web of Science ®Google Scholar
• Tauber E, Kollaritsch H, von Sonnenburg F et al. Randomized, double-blind, placebo-controlled Phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine. J. Infect. Dis.198, 493–499 (2008).
   PubMed Web of Science ®Google Scholar
• Srivastava AK, Putnak JR, Lee SH et al. A purified inactivated Japanese encephalitis virus vaccine made in Vero cells. Vaccine19, 4557–4565 (2001).
   PubMed Web of Science ®Google Scholar
• Lyons A, Kanesa-thasan N, Kuschner RA et al. A Phase 2 study of a purified, inactivated virus vaccine to prevent Japanese encephalitis. Vaccine25, 3445–3453 (2007).
   PubMed Web of Science ®Google Scholar
• Torinawa H, Tomoyoshi K. Long-term stability of Vero cell-derived inactivated Japanese encephalitis vaccine prepared using serum-free medium Vaccine26, 3680–3689 (2008).
   PubMedGoogle Scholar
• Kuzuhara S, Nakamura H, Hayashida K et al. Non-clinical and Phase I clinical trials of a Vero cell-derived inactivated Japanese encephalitis vaccine. Vaccine21, 4519–4526 (2003).
   PubMed Web of Science ®Google Scholar
• Guirakhoo F, Zhang ZX, Chambers TJ et al. Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever–Japanese encephalitis virus (ChimeriVax–JE) as a live, attenuated vaccine candidate against Japanese encephalitis. Virology257, 363–372 (1999).
   PubMed Web of Science ®Google Scholar
• Monath TP, Guirakhoo F, Nichols R et al. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax–JE): Phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J. Infect. Dis.188, 1213–1230 (2003).
   PubMed Web of Science ®Google Scholar
• Gubler DJ. Dengue and dengue hemorrhagic fever. Clin. Microbiol. Rev.11, 480–496 (1998).
   PubMed Web of Science ®Google Scholar
• Edelman R. Dengue vaccines approach the finish line. Clin. Infect. Dis.45, 56–60 (2007).
   Google Scholar
• Durbin AP, Karron RA, Sun W et al. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3´-untranslated region. Am. J. Trop. Med. Hyg.65, 405–413 (2001).
   PubMed Web of Science ®Google Scholar
• Blaney JE Jr, Sathe NS, Hanson CT, Firestone CY, Murphy BR, Whitehead SS. Vaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes of rDEN4 and rDEN4Delta30 with those of DEN1. Virol. J.4, 23 (2007).
   PubMedGoogle Scholar
• Blaney JE Jr, Sathe NS, Goddard L et al. Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3´ untranslated region (3´-UTR) or by exchange of the DENV-3 3´-UTR with that of DENV-4. Vaccine26, 817–828 (2008).
   PubMed Web of Science ®Google Scholar
• Durbin AP, McArthur J, Marron JA et al. The live attenuated dengue serotype 1 vaccine rDEN1D30 is safe and highly immunogenic in healthy adult volunteers. Hum. Vaccin.2, 167–173 (2006).
   PubMed Web of Science ®Google Scholar
• Durbin AP, McArthur JH, Marron JA et al. rDEN2/4D30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naive adults. Hum. Vaccin.2, 255–260 (2006).
   PubMed Web of Science ®Google Scholar
• Durbin AP, Whitehead SS, McArthur J et al. rDEN4D30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers. J. Infect. Dis.191, 710–718 (2005).
   PubMed Web of Science ®Google Scholar
• McArthur JH, Durbin AP, Marron JA et al. Phase I clinical evaluation of rDEN4D30–200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity. Am. J. Trop. Med. Hyg.79, 678–684 (2008).
   PubMed Web of Science ®Google Scholar
• Lai CJ, Monath TP. Chimeric flaviviruses: novel vaccines against dengue fever, tick-borne encephalitis and Japanese encephalitis Adv. Virus Res.61, 469–509 (2003).
   PubMedGoogle Scholar
• Guirakhoo F, Pugachev K, Zhang Z et al. Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J. Virol.78, 4761–4775 (2004).
   PubMed Web of Science ®Google Scholar
• Campbell GL, Marfin AA, Lanciotti RS, Gubler DJ. West Nile virus. Lancet Infect. Dis.2, 519–29 (2002).
   PubMed Web of Science ®Google Scholar
• Elizondo-Quiroga D, Davis CT, Fernandez-Salas I et al. West Nile virus isolation in human and mosquitoes, Mexico. Emerg. Infect. Dis.11, 1449–1452 (2005).
   PubMed Web of Science ®Google Scholar
• Morales MA, Barrandeguy M, Fabbri C et al. West Nile virus isolation from equines in Argentina, 2006. Emerg. Infect. Dis.12, 1559–1561 (2006).
   PubMedGoogle Scholar
• Pepperell C, Rau N, Krajden S et al. West Nile virus infection in 2002: morbidity and mortality among patients admitted to hospital in southcentral Ontario. CMAJ168, 1399–1405 (2003).
   PubMedGoogle Scholar
• Monath TP, Liu J, Kanesa-thasan N et al. A live, attenuated recombinant West Nile virus vaccine. Proc. Natl Acad. Sci. USA103, 6694–6699 (2006).
   PubMed Web of Science ®Google Scholar
• Arroyo J, Miller C, Catalan J et al. ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy. J. Virol.78, 12497–12507 (2004).
   PubMed Web of Science ®Google Scholar
• Lim CK, Takasaki T, Kotaki A, Kurane I. Vero cell-derived inactivated West Nile (WN) vaccine induces protective immunity against lethal WN virus infection in mice and shows a facilitated neutralizing antibody response in mice previously immunized with Japanese encephalitis vaccine. Virology374, 60–70 (2008).
   PubMed Web of Science ®Google Scholar
• Pittman PR, Plotkin SA. Biodefense and special pathogen vaccines. In: Vaccines (5th Edition). Plotkin SA, Orenstein WA, Offit PA (Eds). Saunders Elsevier, PA, USA 1123–1133 (2008).
   Google Scholar
• Murphy FA. Emerging zoonoses: the challenge for public health and biodefense. Prev. Vet. Med.86, 216–223 (2008).
   PubMed Web of Science ®Google Scholar
• Peiris JS, Lai ST, Poon LL et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet361, 1319–1325 (2003).
   PubMed Web of Science ®Google Scholar
• Communicable Diseases Surveillance. Commun. Dis. Intell.20, 356–364 (1996).
   Google Scholar
• Aaskov JG, Mataika JU, Lawrence GW et al. An epidemic of Ross River virus infection in Fiji, 1979. Am. J. Trop. Med. Hyg.30, 1053–1059 (1981).
   PubMedGoogle Scholar
• Kistner O, Barrett N, Brühmann A et al. The preclinical testing of a formaldehyde inactivated Ross River virus vaccine designed for use in humans. Vaccine25, 4845–4852 (2007).
   PubMed Web of Science ®Google Scholar
• Ravi V. Re-emergence of chikungunya virus in India. Indian J. Med. Microbiol.24, 83–84 (2006).
   PubMedGoogle Scholar
• Hochedez P, Jaureguiberry S, Debruyne M et al. Chikungunya infection in travelers. Emerg. Infect. Dis.12, 1565–1567 (2006).
   PubMed Web of Science ®Google Scholar
• Dalla Pozza G, Majori G. First record of Aedes albopictus establishment in Italy. J. Am. Mosq. Control. Assoc.8, 318–320 (1992).
   PubMedGoogle Scholar
• Schuffenecker I, Iteman I, Michault A et al. Genome microevolution of chikungunya viruses causing the Indian Ocean outbreak. PLoS Med.3, 1058–1070 (2006).
   Web of Science ®Google Scholar
• Wang E, Volkova E, Adams AP et al. Chimeric alphavirus vaccine candidates for chikungunya. Vaccine26, 5030–5039 (2008).
   PubMed Web of Science ®Google Scholar
• Qu D, Zheng B, Yao X et al. Intranasal immunization with inactivated SARS–CoV (SARS-associated coronavirus) induced local and serum antibodies in mice. Vaccine23, 924–931 (2005).
   PubMed Web of Science ®Google Scholar
• Qin E, Shi H, Tang L et al. Immunogenicity and protective efficacy in monkeys of purified inactivated Vero-cell SARS vaccine. Vaccine24, 1028–1034 (2006).
   PubMedGoogle Scholar
• Monath TP, Caldwell JR, Mundt W et al. ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain) – a second-generation smallpox vaccine for biological defense. Int. J. Infect. Dis.8(Suppl. 2), 31–44 (2004).
   PubMed Web of Science ®Google Scholar
• Schild GC, Oxford JS, de Jong JC, Webster RG. Evidence for host-cell selection of influenza virus antigenic variants. Nature303, 706–709 (1983).
   PubMed Web of Science ®Google Scholar
• Robertson JS, Bootman JS, Newman R et al. Structural changes in the haemagglutinin which accompany egg adaptation of an influenza A(H1N1) virus. Virology160, 31–37 (1987).
   PubMed Web of Science ®Google Scholar
• Hardy CT, Young SA, Webster RG, Naeve CW, Owens RJ. Egg fluids and cells of the chorioallantoic membrane of embryonated chicken eggs can select different variants of influenza A (H3N2) viruses. Virology211, 302–306 (1995).
   PubMed Web of Science ®Google Scholar
• Robertson JS, Nicolson C, Major D, Robertson EW, Wood JM. The role of amniotic passage in the egg-adaptation of human influenza virus is revealed by haemagglutinin sequence analyses. J. Gen. Virol.74, 2047–2051 (1993).
   PubMed Web of Science ®Google Scholar
• Katz JM, Webster RG. Efficacy of inactivated influenza A virus (H3N2) vaccines grown in mammalian cells or embryonated eggs. J. Infect. Dis.160, 191–198 (1989).
   PubMed Web of Science ®Google Scholar
• Nakamura K, Homma M. Protein synthesis in Vero cells abortively infected with influenza B virus. J. Gen. Virol.56, 199–202 (1981).
   PubMed Web of Science ®Google Scholar
• Lau SC, Scholtissek C. Abortive infection of Vero cells by an influenza A virus (FPV). Virology212, 225–231 (1995).
   PubMed Web of Science ®Google Scholar
• Subbarao K, Chen H, Swayne D et al. Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics. Virology305, 192–200 (2003).
   PubMed Web of Science ®Google Scholar
• Nicolson C, Major D, Wood JM, Robertson JS. Generation of influenza vaccine viruses on Vero cells by reverse genetics: an H5N1 candidate vaccine strain produced under a quality system. Vaccine23, 2943–2952 (2005).
   PubMed Web of Science ®Google Scholar
• WHO. Annex 5. WHO biosafety risk assessment and guidelines for the production and quality control of human influenza pandemic vaccines. WHO, Geneva, Switzerland (2005).
   Google Scholar
• Howard MK, Kistner O, Barrett PN. Pre-clinical development of cell culture (Vero)-derived H5N1 pandemic vaccines. Biol. Chem.389, 569–577 (2008).
   PubMed Web of Science ®Google Scholar
• Montagnon BJ. Polio and rabies vaccines produced in continuous cell lines: a reality for Vero cell line. Develop. Biol. Standard70, 27–47 (1989).
   PubMedGoogle Scholar